Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | AML: ivosidenib is coming

Paresh Vyas • 16 Jun 2019
EHA 2019
Acute Myeloid Leukemia Myelodysplastic Syndromes Ivosidenib

Paresh Vyas, MRCP, FRCP, FRCPath, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, discusses the use of ivosidenib in the treatment of acute myeloid leukemia (AML) and myelodysplasia for patients with a specific genetic abnormality either alone or as part of combination therapy. Speaking at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands, Prof. Vyas also comments that ivosidenib is available in the USA, is being considered by the European Medicines Agency (EMA) and is available in the UK via clinical trials.

More from Paresh Vyas

2:45
Promising emerging therapies for AML and the challenges that remain
Paresh Vyas • 18 Dec 2023
6:11
First-in-human study of the menin-KMT2A inhibitor JNJ-75276617 in R/R acute leukemias
Paresh Vyas • 18 Dec 2023
1:12
Understanding genetic and non-genetic mechanisms involve in AML disease progression
Paresh Vyas • 24 Apr 2023
0:49
Treatment avenues for patients with R/R FLT3-mutated AML: optimizing FLT3 inhibitors
Paresh Vyas • 24 Apr 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
The content of VJHemOnc is intended for healthcare professionals